- The patent covers both MultiCell's drug compositions and immunotherapy platform technologies. The novel drug compositions consist of noncoding double-stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules.
- MultiCell’s therapy presents antigens to immune cells, resulting in protective immunity against tumors and viruses.
- MultiCell is developing therapies for treatment of hepatitis B, hepatitis C, and certain cancers.
One of MultiCell’s anticancer initiatives involves using a very small dsRNA therapy to target cancer by delivering a cytotoxic effect to the cells that have the highest tumor-initiating capacity, such as cancer stem cells. MultiCell’s therapies that are in development are being tested at the preclinical level.